The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.